Diabetic retinopathy is a diabetes-related disease of the retinal neurovascular unit—the interconnected system of blood vessels, neurons, glial cells and supporting tissue that allows the retina to function. It is not glaucoma, and it should not be described using glaucoma mechanisms, prevalence statistics or pressure-lowering treatment language.
What diabetic retinopathy does to the retina
Long-term hyperglycemia can injure retinal capillaries and disrupt the blood-retinal barrier. Early nonproliferative diabetic retinopathy (NPDR) may produce microaneurysms, retinal hemorrhages, lipid exudates and areas of impaired capillary perfusion. Diabetic macular edema can occur at different stages when vascular leakage causes retinal thickening near the macula. In proliferative diabetic retinopathy (PDR), retinal ischemia stimulates abnormal new blood vessels that can bleed, scar and pull on the retina.
Research also supports a neural component: retinal neurons and glial cells may become dysfunctional before or alongside visible vascular lesions. This is why diabetic retinopathy is increasingly understood as a neurovascular disease rather than an isolated “leaky blood vessel” problem.
Symptoms and warning signs
- No noticeable symptoms in early disease
- Blurred or fluctuating vision
- Difficulty reading or seeing fine detail
- Dark spots, floaters or sudden cobweb-like shadows
- Reduced contrast or color perception
- Sudden loss of vision, which requires urgent ophthalmic evaluation
Condition-specific biological mechanisms
Blood-retinal barrier dysfunction
Hyperglycemia, endothelial injury and pericyte loss make retinal capillaries more vulnerable to leakage and closure. Barrier failure contributes to edema; capillary nonperfusion contributes to ischemia and the release of angiogenic signals such as VEGF.
Retinal neurodegeneration
Experimental and clinical evidence describes apoptosis, glial activation, impaired neurotrophic signaling and altered retinal function early in diabetes. These neural changes interact with microvascular injury rather than occurring as a separate disease.
Inflammation, oxidative stress and mitochondrial strain
Chronic metabolic stress can activate inflammatory pathways, increase reactive oxygen species and impair mitochondrial function. These processes may amplify endothelial dysfunction, neuronal stress and vascular permeability.
How diabetic retinopathy is evaluated
Diagnosis and staging belong with an ophthalmologist or retina specialist. Evaluation may include a dilated retinal examination, fundus photography, optical coherence tomography (OCT) for macular edema, OCT angiography, and fluorescein angiography when vascular leakage or nonperfusion must be mapped. Urgent assessment is appropriate for new floaters, flashes, a curtain in the vision or sudden visual loss.
Evidence-based standard care
Management is individualized by disease stage. It commonly includes improving glycemic, blood-pressure and lipid control; anti-VEGF therapy for center-involving diabetic macular edema or proliferative disease; panretinal laser photocoagulation in selected PDR; corticosteroid therapy in selected eyes; and vitrectomy for complications such as non-clearing vitreous hemorrhage or tractional retinal detachment. Patients should continue every treatment and monitoring interval recommended by their retina specialist.
Where NRT may fit
At Netra Eye Institute, NRT is discussed as adjunctive support for the broader biological environment surrounding retinal function. The supportive focus may include autonomic regulation, circulation, oxidative-stress balance, inflammatory balance and whole-person metabolic resilience through individualized acupuncture, traditional East Asian medicine and Ayurvedic approaches.
NRT is not an anti-VEGF substitute, does not reverse retinal detachment, and should not be represented as regenerating permanently lost retinal tissue. Any reported functional change must be interpreted alongside objective retinal findings and ongoing conventional care.
Frequently asked questions
Can diabetic retinopathy progress without symptoms?
Yes. Sight-threatening changes may develop before a person notices visual symptoms, making scheduled diabetic retinal examinations essential.
Does controlled A1C eliminate retinal risk?
Improved glycemic control reduces risk, but duration of diabetes, prior metabolic exposure, blood pressure, kidney disease, lipids, pregnancy and existing retinopathy also influence progression.
Should injections be stopped when vision improves?
No. Injection frequency and discontinuation decisions must be made by the treating retina specialist based on OCT, examination findings and the eye’s response.
Selected references
- Simó R, Hernández C. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014. PubMed.
- Callan A, et al. Cellular and molecular mechanisms of neuronal dysfunction in diabetic retinopathy. 2024. PubMed.
- Wang Z, et al. Recent advances in the treatment and delivery systems of diabetic retinopathy. 2024. PubMed.
- Fang Y, et al. Somatostatin and retinal neurovascular-unit impairment in diabetic retinopathy. 2024. PubMed.
- American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice Pattern. Current edition.
Educational information only. Netra Eye Institute does not diagnose diabetic retinopathy or replace ophthalmologic care. Individual outcomes vary.